ERBB2 and neoplasm: In early clinical trials of trastuzumab for breast cancer, HER2 status was determined by immunohistochemistry (IHC), and a 3+ score corresponded to “more than moderate,” i.e., strong, staining of the “entire tumor-cell membrane... in more than 10 percent of tumor cells” [19].